For many years, beta-blockers have been one of the most common medicines given to people after a heart attack. Doctors around the world have prescribed these drugs to help reduce stress on the heart, lower blood pressure, and prevent future heart problems.
But a major new study is now raising serious questions about whether beta-blockers are equally safe and effective for everyone. Researchers found that women recovering from certain types of heart attacks may actually face higher risks when taking these medications.
The findings come from a large international study called the REBOOT trial. The research was coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and involved hospitals in Spain and Italy.
More than 8,500 patients from 109 hospitals took part in the study, making it one of the largest modern studies ever conducted on beta-blockers after heart attacks.
The results were presented at the European Society of Cardiology Congress in Madrid and published in the European Heart Journal.
Heart attacks happen when blood flow to part of the heart becomes blocked, damaging the heart muscle.
After a heart attack, doctors often prescribe several medications to reduce the risk of future complications. Beta-blockers have long been considered a standard part of treatment because they slow the heart rate and reduce the heart’s workload.
However, much of the older research supporting beta-blockers was performed decades ago, before many modern heart treatments became common. Today, patients often receive faster emergency care, improved procedures, cholesterol-lowering drugs, and better blood-thinning medications.
Because of these advances, scientists wanted to re-examine whether beta-blockers still provide the same benefits for all patients.
The REBOOT trial focused on patients who had experienced a heart attack but did not suffer severe damage to the heart’s pumping ability.
Researchers randomly assigned patients into two groups. One group received beta-blockers along with standard treatment, while the other group received standard care without beta-blockers.
The patients were followed for nearly four years. During this time, researchers carefully tracked deaths, repeat heart attacks, and hospitalizations caused by heart failure.
When scientists analyzed the results, they discovered important differences between men and women.
For men, beta-blockers did not appear to provide clear benefits or major harms. The medication did not significantly change the risk of death, another heart attack, or hospitalization for heart failure.
For women, however, the findings were very different.
Women who took beta-blockers after their heart attack had a significantly higher risk of serious complications compared to women who did not take the drugs. During the follow-up period, women taking beta-blockers showed a 2.7% higher risk of death.
The increased risk was especially noticeable in women whose heart pumping function remained completely normal after the heart attack.
This measurement is called the left ventricular ejection fraction, which describes how well the heart pumps blood. Women with an ejection fraction of 50% or higher appeared to face the greatest risk from beta-blocker treatment.
Interestingly, women with mild heart function problems did not show the same increased risk.
The study also highlighted major differences between male and female heart attack patients more broadly.
Women in the study were generally older than men and were more likely to have other health conditions such as diabetes, high blood pressure, and high cholesterol. Women were also more likely to experience heart attacks that occurred without major blocked arteries, which is a condition that doctors are still trying to better understand.
Despite often facing higher overall risks, women were less likely than men to receive several other recommended treatments after heart attacks. These included cholesterol-lowering statin drugs, antiplatelet medications that reduce blood clotting, and cardiac rehabilitation programs designed to help patients recover.
Overall, women in the study had worse outcomes than men. About 4.3% of women died during the study period compared to 3.6% of men.
Dr. Borja Ibáñez, who led the REBOOT trial, said the findings support earlier smaller studies suggesting that women may respond differently to common heart treatments. He explained that women often have different heart attack patterns and may not always benefit from therapies in the same way as men.
Researchers say the study highlights the need for more personalized medical care. For many years, doctors have often used the same treatment approaches for both men and women. However, growing evidence suggests that biological differences between sexes can affect how diseases develop and how medications work.
Dr. Valentín Fuster, one of the leaders of the study, said scientists have known for years that heart disease often appears differently in women than in men. Now, researchers are beginning to realize that treatments may also need to be different.
The findings could eventually influence future heart treatment guidelines. Doctors may need to carefully consider whether beta-blockers are necessary for women recovering from uncomplicated heart attacks, especially when heart function remains normal.
At the same time, researchers caution that patients should not stop taking beta-blockers without medical advice. Beta-blockers remain very important and life-saving for many heart conditions, including severe heart failure, abnormal heart rhythms, and certain types of heart damage.
More research will still be needed before treatment guidelines officially change. However, the REBOOT trial represents an important step toward understanding how heart treatments may need to be tailored more carefully for men and women.
The study also highlights a larger issue in medicine: many treatments historically have been studied mainly in male patients, while women were underrepresented in research. Scientists now recognize that more sex-specific research is needed to ensure treatments are both safe and effective for everyone.
As doctors continue learning more about these differences, future heart care may become more personalized, helping patients receive treatments that are better matched to their individual biology and health needs.
Copyright © 2026 Knowridge Science Report. All rights reserved.
